**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

An approximately 68-year-old man developed diffuse pneumonitis during treatment with ipilimumab and nivolumab for stage IV cutaneous melanoma of the scalp.

The man had been diagnosed with a stage IVD BRAF wild-type cutaneous melanoma of the scalp with six intracranial metastases, peritoneal metastases, and innumerable bilateral lung metastases in Feb 2017 at the age of 65 years. He underwent bilateral craniotomies for excision of left temporal and right frontal lobe lesions. Pathology revealed melanoma with clear cell and spindle cell features. Treatment with corticosteroids was weaned off, and the next day, he received treatment with nivolumab 1 mg/kg and ipilimumab 3 mg/kg \[*frequencies and routes not stated*\] for stage IV cutaneous melanoma of the scalp. Following two days post first dose of nivolumab and ipilimumab in Apr 2017, he developed productive cough with yellow sputum and dyspnoea, which persisted over the next 5 days. Within one week of this therapy, a physical examination showed hypotension, tachycardia, hypoxia bilateral upper lung crackles without fever. Chest CT showed pulmonary metastases superimposed by new diffuse ground-glass opacification. On the second day of hospitalization, respiratory viral pathogens were evaluated with nasopharyngeal swab indicated the presence of coronavirus HKU1 (non-COVID-19) infection. Blood cultures showed no growth and sputum cultures showed normal respiratory flora. He was diagnosed with checkpoint inhibitor pneumonitis (CIP).

The man was treated with high-dose unspecified corticosteroids. A follow-up chest CT scan in May 2017, showed resolution of ground glass opacification and at the same time, the dose of nivolumab was increased to 3 mg/kg and continued until April 2018 without recurrence of pneumonitis. Brain MRI in April 2018 revealed postsurgical changes without evidence of metastases. Abdominal and chest CT scans demonstrated a decrease in size and number of pulmonary nodules and right peritoneal nodules. 18F-fluorodeoxyglucose (FDG) positron emission tomography revealed no proof of FDG-avid disease, supporting the possibility of a metabolic complete systemic and cerebral response. Treatment with nivolumab was stopped post discussion of the known risks and benefits of continuing and stopping therapy. Thereafter, he underwent clinical evaluation, brain MRI and CT scans every 3 months. In February 2020, at most recent follow-up, 3 years after initial diagnosis and nearly 2 years of immunotherapy, he remained free of disease progression.
